Bicycle Therapeutics/$BCYC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Bicycle Therapeutics
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Ticker
$BCYC
Sector
Primary listing
Employees
305
Headquarters
Website
BCYC Metrics
BasicAdvanced
$456M
-
-$3.62
1.47
-
Price and volume
Market cap
$456M
Beta
1.47
52-week high
$24.14
52-week low
$6.10
Average daily volume
348K
Financial strength
Current ratio
10.664
Quick ratio
10.329
Long term debt to equity
0.159
Total debt to equity
0.929
Interest coverage (TTM)
-1,442.89%
Profitability
EBITDA (TTM)
-283.23
Gross margin (TTM)
-744.21%
Net profit margin (TTM)
-884.51%
Operating margin (TTM)
-1,023.40%
Effective tax rate (TTM)
0.87%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-20.59%
Return on equity (TTM)
-34.59%
Valuation
Price to revenue (TTM)
16.072
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-1.883
Free cash flow yield (TTM)
-53.10%
Free cash flow per share (TTM)
-3.494
Growth
Revenue change (TTM)
-23.20%
Earnings per share change (TTM)
12.26%
3-year revenue growth (CAGR)
23.49%
3-year earnings per share growth (CAGR)
1.97%
What the Analysts think about BCYC
Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.
Bulls say / Bears say
Net losses widened to $79.0 million in Q2 2025, up from $39.8 million in the same period last year, highlighting ongoing unprofitability. (SEC)
An accumulated deficit of $820.5 million as of June 30, 2025, indicates significant historical cash burn and a continued lack of profitability. (SEC)
The company expects operating expenses to increase substantially as clinical trials progress, and has stated it will require additional funding beyond its current cash resources, which could dilute existing shareholders. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2025.
BCYC Financial Performance
Revenues and expenses
BCYC Earnings Performance
Company profitability
BCYC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicycle Therapeutics stock?
Bicycle Therapeutics (BCYC) has a market cap of $456M as of November 11, 2025.
What is the P/E ratio for Bicycle Therapeutics stock?
The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of November 11, 2025.
Does Bicycle Therapeutics stock pay dividends?
No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of November 11, 2025.
When is the next Bicycle Therapeutics dividend payment date?
Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.